Zealand Pharma A/S Stock price

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 05:43:31 22/02/2024 pm IST 5-day change 1st Jan Change
463 DKK +0.30% Intraday chart for Zealand Pharma A/S -6.02% +23.79%

Financials

Sales 2023 * 347M 50.51M 4.18B Sales 2024 * 1.4B 203M 16.84B Capitalization 28.68B 4.18B 346B
Net income 2023 * -556M -80.98M -6.7B Net income 2024 * 186M 27.09M 2.24B EV / Sales 2023 * 77.6 x
Net cash position 2023 * 1.75B 255M 21.12B Net cash position 2024 * 3.2B 466M 38.57B EV / Sales 2024 * 18.2 x
P/E ratio 2023 *
-36 x
P/E ratio 2024 *
312 x
Employees 249
Yield 2023 *
-
Yield 2024 *
-
Free-Float 93.22%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.30%
1 week-6.02%
Current month-2.16%
1 month+1.67%
3 months+39.16%
6 months+67.51%
Current year+23.79%
More quotes
1 week
457.60
Extreme 457.6
502.00
1 month
431.00
Extreme 431
505.50
Current year
342.20
Extreme 342.2
505.50
1 year
205.60
Extreme 205.6
505.50
3 years
69.55
Extreme 69.55
505.50
5 years
69.55
Extreme 69.55
505.50
10 years
58.00
Extreme 58
505.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 01/10/01
Director of Finance/CFO - 01/22/01
Chief Tech/Sci/R&D Officer - 04/20/04
Members of the board TitleAgeSince
Director/Board Member 66 04/19/04
Chairman 69 01/15/01
Director/Board Member 68 19/18/19
More insiders
Date Price Change Volume
22/24/22 462.6 +0.22% 150 775
21/24/21 461.6 -5.14% 528,743
20/24/20 486.6 +1.04% 380,556
19/24/19 481.6 -0.66% 160,897
16/24/16 484.8 -1.38% 249,894

Delayed Quote Nasdaq Copenhagen, February 22, 2024 at 05:28 pm IST

More quotes
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
461.6 DKK
Average target price
459.2 DKK
Spread / Average Target
-0.53%
Consensus
1st Jan change Capi.
+23.79% 4 161 M $
+3.13% 108 B $
+8.49% 102 B $
+6.32% 23 677 M $
-12.13% 22 046 M $
-7.45% 18 877 M $
-16.39% 15 725 M $
-0.84% 13 001 M $
+37.19% 12 375 M $
+0.77% 12 086 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Zealand Pharma A/S - Nasdaq Copenhagen
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer